# US 2024/0200130 A1 · Highly sensitive in vitro assays to define substrate preferences and sites of nucleic-acid binding, modifying, and cleaving agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0200130 A1
- Document ID: US20240200130A1
- Status: Published application
- Kind: A1
- Application number: 18/402,501
- Filed: 2024-01-02
- Published: 2024-06-20
- Earliest claimed: 2018-04-17
- Assignees: The General Hospital Corporation
- Applicants: The General Hospital Corporation
- Inventors: J. Keith Joung; Vikram Pattanayak; Karl Petri
- Web page: https://patentgrep.com/patent/US20240200130A1

## CPC

- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Q 1/6874: involving nucleic acid arrays, e.g. sequencing by hybridisation
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/1058: {Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms}
- C12Q 1/6827: for detection of mutation or polymorphism
- C12Q 1/6853: using modified primers or templates
- C12Y 305/04005: Cytidine deaminase (3.5.4.5)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

Methods and compositions for performing highly sensitive in vitro assays to define substrate preferences and off-target sites of nucleic-acid binding, modifying, and cleaving agents.

## Claims

### Claim at position 1

1-2. (canceled)

### Claim 3

A method of identifying double stranded DNA sequences that are modified by a base editing enzyme, the method comprising:
(i) providing a plurality of linear dsDNA oligonucleotides of known sequences, each oligonucleotide having a 5′ end and a 3′ end and bearing two copies of a unique identifier sequence at or near both the 3′ and 5′ ends of the oligonucleotide, and a common sequence that is present in each one of the oligonucleotides in the plurality;
(ii) incubating the plurality linear dsDNA oligonucleotides in the presence of a base editing enzyme under conditions sufficient for modification to occur;
(iii) amplifying the oligonucleotides with a polymerase that converts edited base pairs to equal mixtures of canonical base pairs during DNA synthesis, optionally wherein a dATP nucleotide is incorporated across from dU or a dCTP nucleotide is incorporated across from dI, such that an oligonucleotide that has been modified by the base editing enzyme will be amplified as a mixture of the original barcode-linked sequence from the pre-treatment library and also a modified sequence that contains substitutions; and
(iv) determining the sequences of the amplified oligonucleotides, thereby identifying double stranded DNA sequences that are modified by the base editing enzyme.

### Claim at position 3

4-7. (canceled)

### Claim 8 (depends on 3)

The method of claim 3, wherein the linear dsDNA oligonucleotides comprise:
(i) a set of all potential off-target sequences in a reference genome bearing up to a certain number of mismatches relative to an identified on-target site (analogous to genomic DNA libraries);
(ii) a comprehensive set of potential off-target sites bearing up to a certain number of mismatches;
(iii) a library of potential off-target sequences present in a set of variant genomes from defined populations, optionally genomic DNA libraries designed to reflect DNA sequence variants present in a population of individuals; or
(iv) another relevant defined set of potential off-target sites, optionally oncogene hotspots or sequences from tumor suppressor genes.

### Claim 9 (depends on 3)

The method of claim 3, wherein:
the linear DNA library members are first synthesized as individual single-stranded DNA sequences, optionally on high-density oligonucleotide arrays; and
the single-stranded DNA sequences are converted into double-stranded DNA molecules by priming against the common sequence, optionally before or after being released from the chip.

### Claim 10

(canceled)

### Claim 11 (depends on 3)

The method of claim 3, wherein the linear DNA library members comprise 1,000 to 1011 different sequences.

### Claim 12 (depends on 3)

The method of claim 3, wherein the pre enriched linear DNA library members comprise sequences that are 50 to 500 bp long.

### Claim 13 (depends on 3)

The method of claim 3, wherein the base editing enzyme is a cytidine deaminase that converts deoxycytidine to deoxyuridine or an adenine base editing enzyme that converts deoxyadenine to deoxyinosine.

### Claim 14 (depends on 3)

The method of claim 3, wherein the polymerase that converts edited base pairs to equal mixtures of canonical base pairs is a uracil tolerant polymerase that converts dU:dG base pairs to equal mixtures of dT:dA and dC:dG base pairs, or that converts dI:dT base pairs to equal mixtures of dA:dT and dG:dC base pairs.

### Claim 15

(canceled)

### Claim 16 (depends on 3)

The method of claim 3, wherein during the amplifying in step (iii), a dATP nucleotide is incorporated across from dU or a dCTP nucleotide is incorporated across from dI.

### Claim 17 (depends on 8)

The method of claim 8, wherein the linear dsDNA oligonucleotides comprise a set of all potential off-target sequences in a reference genome bearing up to a certain number of mismatches relative to an identified on-target site (analogous to genomic DNA libraries).

### Claim 18 (depends on 8)

The method of claim 8, wherein the linear dsDNA oligonucleotides comprise a comprehensive set of potential off-target sites bearing up to a certain number of mismatches.

### Claim 19 (depends on 8)

The method of claim 8, wherein the linear dsDNA oligonucleotides comprise a library of potential off-target sequences present in a set of variant genomes from defined populations, optionally genomic DNA libraries designed to reflect DNA sequence variants present in a population of individuals.

### Claim 20 (depends on 8)

The method of claim 8, wherein the linear dsDNA oligonucleotides comprise a defined set of potential off-target sites.

### Claim 21 (depends on 20)

The method of claim 20, wherein the defined set of potential off target sites comprise oncogene hotspots or sequences from tumor suppressor genes.

### Claim 22 (depends on 9)

The method of claim 9, wherein the linear DNA library members are first synthesized as individual single-stranded DNA sequences on high-density oligonucleotide arrays.

### Claim 23 (depends on 9)

The method of claim 9, wherein the single stranded DNA sequences are converted into double-stranded DNA molecules by priming against the common sequence before being released from the chip.

### Claim 24 (depends on 9)

The method of claim 9, wherein the single stranded DNA sequences are converted into double-stranded DNA molecules by priming against the common sequence after being released from the chip.
